Durvalumab,Tremelimumab
Astrazeneca
['immuchec', '2mo', 'durva', '52mo']
 just presented our immuchec at 52mo phs-ii to identify activity for best combo of ctx + durva/treme in 1st line #cholangiocarcinoma epigenetic immune profiling for pd1/lag3 to identify responder to ici or ctx #livertwitter 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine